SymbioCellTech, LLC

📍 Salt Lake City, United States🗓 Founded 2014👥 6 employees💰 Last funded Jul 2014
Biotechnology🌐 symbiocelltech.com
Website LinkedIn
SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2014
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in SymbioCellTech, LLC?
SymbioCellTech, LLC has 1 investor on record on gritt.io, including 1 early-stage backers.
When did SymbioCellTech, LLC last raise funding?
The most recent investment in SymbioCellTech, LLC recorded on gritt.io was in July 2014.
When was SymbioCellTech, LLC founded?
SymbioCellTech, LLC was founded in 2014.
What industry is SymbioCellTech, LLC in?
SymbioCellTech, LLC operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is SymbioCellTech, LLC based?
SymbioCellTech, LLC is headquartered in Salt Lake City, United States.